Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of “Buy” by Analysts

Zymeworks Inc. (NASDAQ:ZYME) has received an average rating of “Buy” from the seven brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $33.00.

Several equities research analysts have weighed in on the stock. HC Wainwright upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. B. Riley upgraded Zymeworks to a “strong-buy” rating in a research note on Thursday, October 9th. Zacks Research cut Zymeworks from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Wells Fargo & Company raised Zymeworks from an “equal weight” rating to an “overweight” rating and set a $33.00 price target for the company in a report on Friday, December 12th. Finally, Wall Street Zen downgraded shares of Zymeworks from a “buy” rating to a “hold” rating in a report on Saturday, November 8th.

Zymeworks Price Performance

Shares of Zymeworks stock opened at $23.16 on Tuesday. The company has a market capitalization of $1.73 billion, a P/E ratio of -27.57 and a beta of 1.30. The business has a 50-day moving average price of $24.32. Zymeworks has a one year low of $9.03 and a one year high of $28.49.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $27.61 million for the quarter, compared to the consensus estimate of $28.27 million. Zymeworks had a negative net margin of 47.16% and a negative return on equity of 19.25%.

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.